Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of lanreotide Autogel 120 mg in non-functioning entero-pancreatic neuroendocrine tumors
2008-004019-36Phase 3Completed
- Sponsor
- Ipsen
- Start
- Nov 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanreotide in Gastroenteropancreatic neuroendocrine tumor (GEPNET), sponsored by Ipsen. Primary endpoints: Incidence of adverse events and Other safety endpoints. Started Nov 2008; status: completed.
02
Drugs
lanreotide
03
Conditions
Gastroenteropancreatic neuroendocrine tumor (GEPNET)
Beyond the preview
Go deeper on 2008-004019-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004019-36.